Key Takeaways for Dentists Considering a DSO Sale
- DSO buyers in 2026 apply strict financial and operational thresholds, such as minimum adjusted EBITDA, operatory count, and payer mix, before seriously engaging with a practice.
- Knowing how your practice compares with these criteria can be the essential first step in deciding whether a DSO sale, private-buyer transaction, or other transition path fits your goals.
- McLerran & Associates provides side-by-side comparisons of DSO versus private-buyer offers, modeling real after-tax proceeds and work-back commitments so sellers can make informed decisions.
- Preparing a defensible, CPA-led EBITDA analysis and maintaining strong operational metrics, including hygiene production, lease terms, and technology, can help protect deal value through quality-of-earnings scrutiny.
- Get a free benchmarking analysis from McLerran & Associates to see how your practice compares with 2026 DSO requirements before you speak with any buyer.
What DSO Buyers Actually Require in 2026
DSO buyers evaluate practices against a defined set of financial and operational thresholds. The table below reveals a key pattern: DSOs have shifted away from fixed numerical requirements toward ranges that depend on buyer type and practice profile, so your practice may qualify with one DSO platform while falling short of another’s criteria. Practices that fall short of these benchmarks are often better suited to a doctor-to-doctor transaction or a roll-up into a neighboring DSO location rather than a standalone acquisition.
| Criterion | Minimum Threshold | Preferred / Competitive Range |
|---|---|---|
| Annual Collections | Varies by buyer and practice type | Higher collection practices |
| Adjusted EBITDA | Varies by buyer | Multi-location dental groups with $1M+ adjusted EBITDA command the higher 8x–11x multiples from DSOs in 2026. |
| Operatories | 5 | 5+ |
| Active Patient Count | Varies by buyer | Higher patient counts preferred |
| Government Payer Concentration | Limited concentration | Commercial-insurance-dominant mix |
| Post-Close Work-Back | DSO buyers typically require 3-5 years of post-close work as an associate dentist | 3–5 years |
| Deal Structure (typical) | 60% cash at close | 60–75% cash, 15–30% rollover equity, 1–3 year earnout |
How McLerran Structures a DSO Sale Versus a Private-Buyer Sale
The first step is clarifying your options, not committing to a single path. McLerran & Associates works both the private-buyer (doctor-to-doctor) and DSO markets in roughly equal measure, so clients receive a genuine side-by-side comparison rather than a push toward whichever lane an advisor happens to know best.
The two markets can value the same practice very differently. A practice generating $2M in revenue with $400K in adjusted EBITDA can be valued at roughly 65–85% of collections by a private individual buyer, while a DSO buyer may apply a multiple of EBITDA, which can create a 40–80% difference in headline value. The DSO headline number usually includes rollover equity, earnouts, and a multi-year employment commitment, so the comparison works best when you model real after-tax proceeds over time, not just the initial figure.
Across roughly 2,000 successful practice sales and approximately $2 billion in closed transaction volume, McLerran & Associates has achieved a transaction rate of roughly 85–90%, compared with an industry norm closer to 35–40%. That outcome rests on a four-part process: Understand Your Options, Create Competition, Find The Right Fit, and Maximize Your Outcome.
What Is a DSO Buyer in Practical Terms?
A DSO buyer is a management services organization, typically backed by private equity, that acquires the business assets of a dental practice, then provides administrative, operational, and infrastructure support while the clinical entity continues to operate under the dentist’s license. DSO buyers range from regional roll-ups operating 5 to 75 locations to national platforms with hundreds of offices and institutional capital behind them.
Because DSO buyers negotiate acquisitions every week, an unrepresented seller faces a significant information gap. McLerran & Associates addresses this by creating competition, running a structured, auction-style bid process that typically spans 45 to 60 days and generates around 10 offers from a vetted pool of well-qualified buyers. DSOs known for poor post-close environments are blacklisted and do not reach the table.
CPA-led EBITDA analysis sits at the center of that process. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is the profitability metric DSO buyers use to set their offers. A normalization of $200,000 at a 5x multiple of EBITDA produces $1 million in additional enterprise value, so every add-back, meaning a discretionary or non-recurring expense added back to reported earnings to show true profitability, carries real dollar consequences. McLerran controls the narrative around EBITDA from the outset, so the number that goes to market is defensible and less vulnerable to quiet erosion during due diligence.
What the “2-Year Rule” Really Means for Dentists
The “2-year rule” refers to the post-close employment commitment DSO buyers require from a selling dentist. Most DSO dental acquisitions require the selling dentist to continue working at the practice for a specified period, typically 3 to 5 years as an associate dentist.
This commitment exists because a significant portion of a practice’s revenue can be tied to the selling dentist’s clinical relationships. From the seller’s perspective, it often means wearing three hats at once. You act as a seller focused on cash at close and deal terms, a partner who needs to understand what the DSO will and will not provide operationally, and an investor, because rollover equity in DSO dental acquisitions can range from 10–20% for a solo practice up to 25–35% for platform-scale groups, which makes the DSO’s financial health a direct concern.
McLerran & Associates vets buyers like investments, evaluating a DSO’s profitability, growth trajectory, management team, and private equity backing before any client sits across the table from them. Up to roughly 40% of a DSO deal can be paid in equity rather than cash, so partnering with an undercapitalized buyer can put a material share of the seller’s proceeds at risk.
Model your specific work-back scenarios with McLerran & Associates by requesting a confidential discovery call to compare 2-, 3-, and 5-year commitment structures and how equity and earnouts behave under different outcomes.
Quality-of-Earnings Defense: Protecting Your Agreed Value
Quality of earnings, or QoE, is the due-diligence process where a buyer’s accounting team scrutinizes every EBITDA add-back a seller has claimed. This stage is where poorly prepared deals can get re-traded, meaning the buyer reduces the agreed purchase price after the letter of intent (LOI) is signed because the seller cannot defend key adjustments.
Buyers commonly challenge EBITDA adjustments on several grounds:
- Add-backs that are large relative to total EBITDA
- Recurring “one-time” items that appear every year
- Unbacked adjustments that lack documentation
- Cost savings that have not actually been implemented
Insufficient documentation of normalizations can arouse suspicion during due diligence. Supporting documentation works best when organized systematically in the data room, with clear references to a standardization table.
- Invoices for claimed expenses
- Contracts that support add-back classifications
- Management decisions documented in writing
- Cross-references linking each item to the standardization table
McLerran & Associates builds diligence-grade EBITDA analysis before a practice goes to market, not after an LOI is signed. Every add-back is documented, mapped to the general ledger, and structured to be defensible. When a buyer’s QoE team pushes back, McLerran defends the number and, where appropriate, reminds buyers that other vetted bidders remain in the process, which can help keep agreed values from eroding near the finish line.
Maximize Your Outcome: Preparation Steps for Your Practice
DSO buyers often apply operational screens before they advance to earnings-quality analysis. The checklist below reflects criteria that many buyers evaluate in 2026.
Financial Preparation
- Compile 3 full years of profit-and-loss statements and tax returns.
- Identify and document every discretionary, personal, and non-recurring expense, because these add-backs can increase your adjusted EBITDA.
- Confirm your government payer concentration is limited, since higher concentrations can suppress multiples.
- Review accounts receivable aging, as buyers scrutinize credit-balance management and collection efficiency.
Operational Preparation
- Reduce owner dependence so no single provider exceeds 35% of total production in an ideal DSO acquisition profile.
- Confirm hygiene production sits at 28–35% of total collections with pre-booking rates above 85%.
- Document written standard operating procedures (SOPs) and verify alignment with your practice management software.
- Ensure your lease has sufficient term remaining, because a lease with only 2 years left can reduce sale price by 10–25%.
- Confirm technology infrastructure is current, since DSOs review technology during due diligence as a factor that can support premium multiples.
Deal-Term Preparation
- Understand the difference between joint-venture equity, which typically pays distributions but has a lower upside ceiling, and holding-company equity, which usually does not pay distributions but can offer a higher upside, and confirm which structure a given buyer offers, because this shapes both your liquidity timeline and your potential upside.
- Once you understand the equity structure, push for non-punitive earnout terms that protect your payout if integration disrupts performance. Pro-rata provisions can allow a near-miss on an EBITDA target to pay most of the earnout, and a later start date can account for the buyer’s transition period.
- Confirm the buyer will assume current employees with substantially similar roles and compensation for at least 6–12 months post-close, since staff continuity can directly affect whether you achieve earnout targets.
Frequently Asked Questions
What is the minimum EBITDA a DSO requires to acquire a dental practice?
The qualifying floor can vary by buyer type, but most formal DSO platforms engage seriously with practices generating substantial adjusted EBITDA, with national-scale platforms generally requiring $1 million or more in EBITDA to justify their integration overhead. Practices with lower adjusted EBITDA are typically better suited to a doctor-to-doctor transaction. The profitability metric explained earlier usually gets calculated after normalizing out the owner’s personal and non-recurring expenses.
What are the red flags that can kill a DSO deal?
Several issues can derail a DSO acquisition after an LOI is signed. High government payer concentration can suppress multiples or cause buyers to withdraw. Extreme owner dependence, where the selling dentist produces the majority of revenue with no associate coverage, raises concerns about revenue continuity post-close. A short lease with limited renewal options introduces financing risk for the buyer.
Undocumented or aggressive EBITDA add-backs that cannot be mapped to the general ledger are frequently challenged during quality-of-earnings review and can result in a re-trade, meaning a reduction in the agreed purchase price. Accounts receivable problems, compliance gaps, and staff turnover are also common diligence concerns that can surface late in the process.
How does a DSO deal compare to a private-buyer deal in terms of total proceeds?
Total proceeds can depend heavily on practice size, profitability, and the specific deal structure. DSO buyers apply EBITDA multiples to value practices, while private individual buyers typically apply a percentage of collections or a multiple of seller’s discretionary earnings. For larger practices, the DSO headline number can be materially higher, but that headline often includes rollover equity, earnouts, and a multi-year employment commitment, so not all of it is guaranteed cash at close.
A private-buyer deal typically delivers a higher percentage of proceeds as immediate cash with a much shorter post-sale work-back of 30 to 90 days. The most useful comparison usually involves modeling real after-tax proceeds across both paths over a defined time horizon, which is the side-by-side analysis McLerran & Associates prepares for clients considering both options.
Can a practice owner negotiate the length of the post-close work-back period?
Practice owners can often negotiate the work-back period, although the degree of flexibility can depend on the buyer and the practice’s circumstances. The standard DSO work-back commitment runs 3 to 5 years, and buyers use it to support revenue continuity and patient retention. Sellers who have already reduced their chair time significantly, with an associate carrying a meaningful share of production, may have more leverage to negotiate a shorter commitment or a reduced schedule.
Other negotiable terms can include minimum and maximum schedule requirements, associate compensation rate, exit rights if the DSO breaches the agreement, and protections for clinical autonomy. A sell-side advisor who structures these deals regularly can help identify which terms are movable with a given buyer and can work to secure non-punitive earnout provisions.
Next Step: Talk Through Your Transition Options
A practice owner sells once. A DSO negotiates acquisitions every week. The information gap between those two positions is real, and that gap can be where the outcome of a transition is won or lost. With a track record built on the 2,000+ transactions and $2 billion in volume mentioned earlier, McLerran works both the private-buyer and DSO markets in roughly equal measure so every client receives a genuine side-by-side comparison rather than a push toward one path.
McLerran does not simply list practices. The firm sells them with CPA-led EBITDA analysis that can hold up under buyer scrutiny, a structured competitive process that typically generates around 10 offers, and quality-of-earnings defense that helps keep agreed values from eroding at the finish line.
Request a confidential discovery call with McLerran & Associates to discuss your practice, your goals, and your options. You can also reach the team directly at (512) 900-7989 or at info@dentaltransitions.com.
